Carson Lab Recent Publications

February 2017 – Present

To reference more of Dr. Carson’s publications please go to:


(Reference:  Carson WE)


Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.

Sun SH, Benner B, Savardekar H, Lapurga G, Good L, Abood D, Nagle E, Duggan M, Stiff A, DiVincenzo MJ, Suarez-Kelly LP, Campbell A, Yu L, Wesolowski R, Howard H, Shah H, Kendra K, Carson WE.

Front Immunol. 2021 Oct 12;12:740890. doi: 10.3389/fimmu.2021.740890.

PMID: 34712230; PMCID: PMC8547308.


Characterization of inflammatory changes in the breast cancer associated adipose tissue and comparison to the unaffected contralateral breast.

Blaszczak AM, Quiroga D, Jalilvand A, Torres Matias GS, Wright VP, Liu J, Yu L, Bradley D, Hsueh WA, Carson WE 3rd.

Surg Oncol. 2021 Dec;39:101659. doi: 10.1016/j.suronc.2021.101659. Epub 2021 Sep 9.

PMID: 34534729; PMCID: PMC8671189.


Loss of miR-1469 expression mediates melanoma cell migration and invasion.

DiVincenzo MJ, Barricklow Z, Schwarz E, Moufawad M, Howard JH, Yu L, Chung C, Gru AA, Carson WE 3rd.

PLoS One. 2021 Sep 1;16(9):e0256629. doi: 10.1371/journal.pone.0256629.

PMID: 34469478; PMCID: PMC8409617.


Antibody Conjugation of Fluorescent Nanodiamonds for Targeted Innate Immune Cell Activation.

Suarez-Kelly LP, Sun SH, Ren C, Rampersaud IV, Albertson D, Duggan MC, Noel TC, Courtney N, Buteyn NJ, Moritz C, Yu L, Yildiz VO, Butchar JP, Tridandapani S, Rampersaud AA, Carson WE 3rd.

ACS Appl Nano Mater. 2021 Mar 26;4(3):3122-3139. doi: 10.1021/acsanm.1c00256. Epub 2021 Mar 11.

PMID: 34027313; PMCID: PMC8136585.


Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.

Good L, Benner B, Carson WE.

Cancer ImmunolImmunother. 2021 Sep;70(9):2439-2451. doi: 10.1007/s00262-021-02908-5. Epub 2021 Apr 5.

PMID: 33818636; PMCID: PMC8019691.


Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer.

Benner B, Carson WE.

J Hematol Oncol. 2021 Jan 13;14(1):15. doi: 10.1186/s13045-020-00999-8.

PMID: 33441177; PMCID: PMC7805262.


Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma.

DiVincenzo MJ, Latchana N, Abrams Z, Moufawad M, Regan-Fendt K, Courtney NB, Howard JH, Gru AA, Zhang X, Fadda P, Carson WE.

Melanoma Res. 2020 Oct;30(5):455-464. doi: 10.1097/CMR.0000000000000692.

PMID: 32804708; PMCID:PMC7484309.


Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.

Wesolowski R, Stiff A, Quiroga D, McQuinn C, Li Z, Nitta H, Savardekar H, Benner B, Ramaswamy B, Lustberg M, Layman RM, Macrae E, Kassem M, Williams N, Sardesai S, VanDeusen J, Stover D, Cherian M, Mace TA, Yu L, Duggan M, Carson WE 3rd.

BMC Cancer. 2020 May 19;20(1):445. doi: 10.1186/s12885-020-06949-4.

PMID: 32429929; PMCID: PMC7236344.


Evidence for interaction of the NLRP3 inflammasome and Bruton’s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta.

Benner B, Scarberry L, Stiff A, Duggan MC, Good L, Lapurga G, Butchar JP, Tridandapani S, Carson WE.

Oncoimmunology. 2019 Sep 5;8(11):1659704. doi: 10.1080/2162402X.2019.1659704.

PMID: 31646085; PMCID: PMC6791459.


An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.

Pinette A, McMichael E, Courtney NB, Duggan M, Benner BN, Choueiry F, Yu L, Abood D, Mace TA, Carson WE 3rd.

Cancer Immunol Immunother. 2019 Aug;68(8):1379-1389. doi: 10.1007/s00262-019-02372-2. Epub 2019 Jul 23.

PMID: 31338557; PMCID: PMC7032639.

A phase I/II trial of cetuximab in combination with interleukin-12 administered to patients with unresectable primary or recurrent head and neck squamous cell carcinoma.

McMichael EL, Benner B, Atwal LS, Courtney NB, Mo X, Davis ME, Campbell AR, Duggan MC, Williams K, Martin K, Levine K, Olaverria Salavaggione GN, Noel T, Ganju A, Uppati S, Paul B, Olencki T, Teknos TN, Savvides P, Tridandapani S, Byrd JC, Caligiuri MA, Liu SV, Carson WE.

Clin Cancer Res. 2019 May 29. pii: clincanres.2108.2018. doi: 10.1158/1078-0432.CCR-18-2108. [Epub ahead of print]

Benner B, Scarberry L, Suarez-Kelly LP, Duggan MC, Campbell AR, Smith E, Lapurga G, Jiang K, Butchar JP, Tridandapani S, Howard JH, Baiocchi RA, Mace TA, Carson WE 3rd.

J Immunother Cancer. 2019 May 28;7(1):140. doi: 10.1186/s40425-019-0622-0. 

PMID:  31138333

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.

Duggan MC, Regan-Fendt K, Olaverria Salavaggione GN, Howard JH, Stiff AR, Sabella J, Latchana N, Markowitz J, Gru A, Tridandapani S, Eisfeld AK, de la Chapelle A, Carson WE.

Melanoma Res. 2019 May 20. doi: 10.1097/CMR.0000000000000623. [Epub ahead of print]

PMID:  31116161

Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature.

Suarez-Kelly LP, Yu L, Kline D, Schneider EB, Agnese DM, Carson WE.

Hered Cancer Clin Pract. 2019 Mar 25;17:12. doi: 10.1186/s13053-019-0110-z. eCollection 2019.

PMID:  30962859

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004/jnccn.2019.0018.

PMID:  30959471

Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function.

Mace TA, Ware MB, King SA, Loftus S, Farren MR, McMichael E, Scoville S, Geraghty C, Young G, Carson WE 3rd, Clinton SK, Lesinski GB.

Sci Rep. 2019 Mar 25;9(1):5068. doi: 10.1038/s41598-019-41687-z.

PMID:  30911044

Emerging roles of and therapeutic strategies targeting BRD4 in cancer.

White ME, Fenger JM, Carson WE 3rd.

Cell Immunol. 2019 Mar;337:48-53. doi: 10.1016/j.cellimm.2019.02.001. Epub 2019 Feb 4. Review.

PMID:  30832981

Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.

Regan-Fendt KE, Xu J, DiVincenzo M, Duggan MC, Shakya R, Na R, Carson WE 3rd, Payne PRO, Li F.

NPJ Syst Biol Appl. 2019 Feb 26;5:6. doi: 10.1038/s41540-019-0085-4. eCollection 2019.

PMID:  30820351

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.

McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE 3rd, Butchar J, Tridandapani S, Hertlein E, Castro CE, Muthusamy N, Byrd JC.

Blood Adv. 2019 Feb 12;3(3):447-460. doi: 10.1182/bloodadvances.2018025684.

PMID:  30737226

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.

Suarez-Kelly LP, Levine KM, Olencki TE, Del Campo SEM, Streacker EA, Brooks TR, Karpa VI, Markowitz J, Bingman AK, Geyer SM, Kendra KL, Carson WE.

Cancer Immunol Immunother. 2019 Apr;68(4):619-629. doi: 10.1007/s00262-019-02308-w. Epub 2019 Feb 6. No abstract available.

PMID:  30725205

Effect of topical microporous polysaccharide hemospheres on the duration and amount of fluid drainage following mastectomy: a prospective randomized clinical trial.

Suarez-Kelly LP, Pasley WH, Clayton EJ, Povoski SP, Carson WE, Rudolph R.

BMC Cancer. 2019 Jan 23;19(1):99. doi: 10.1186/s12885-019-5293-1.

PMID:  30674296

Concurrent phyllodes tumor, eccrine carcinoma, and multinodular goiter 20 years after radiotherapy for Hodgkin lymphoma.

Quinn KM, Tozbikian G, Carson WE.

Clin Case Rep. 2018 Nov 6;6(12):2498-2503. doi: 10.1002/ccr3.1854. eCollection 2018 Dec.

PMID:  30564357

Unusual recurrence of breast cancer in a BRCA-variant patient after fat grafting.

Skendelas JP, Lee C, Mangino A, Carson WE 3rd.

Clin Case Rep. 2018 Oct 31;6(12):2457-2462. doi: 10.1002/ccr3.1861. eCollection 2018 Dec.

PMID:  30564348

Pilot randomized controlled trial of a symptom cluster intervention in advanced cancer.

Wells-Di Gregorio SM, Marks DR, DeCola J, Peng J, Probst D, Zaleta A, Benson D, Cohn DE, Lustberg M, Carson WE, Magalang U.

Psychooncology. 2018 Oct 18. doi: 10.1002/pon.4912. [Epub ahead of print]

PMID:  30335211


Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.

Olaverria Salavaggione GN, Duggan MC, Carson WE.

Melanoma Res. 2018 Oct;28(5):390-397. doi: 10.1097/CMR.0000000000000474.

PMID:  30020196


Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma.

Latchana N, DiVincenzo MJ, Regan K, Abrams Z, Zhang X, Jacob NK, Gru AA, Fadda P, Markowitz J, Howard JH, Carson WE 3rd.

J Surg Oncol. 2018 Sep;118(3):501-509. doi: 10.1002/jso.25163. Epub 2018 Aug 21.

PMID:  30132912


Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.

Buteyn NJ, Fatehchand K, Santhanam R, Fang H, Dettorre GM, Gautam S, Harrington BK, Henderson SE, Merchand-Reyes G, Mo X, Benson DM, Carson WE 3rd, Vasu S, Byrd JC, Butchar JP, Tridandapani S. Int Immunol. 2018 Jul 24;30(8):375-383. doi: 10.1093/intimm/dxy040.

PMID:  29868798


Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.

Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd. Cancer Immunol Res. 2018 Jun;6(6):671-684. doi: 10.1158/2326-6066.CIR-17-0343. Epub 2018 Apr 5.

PMID:  29622581


Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors.

Lai X, Stiff A, Duggan M, Wesolowski R, Carson WE 3rd, Friedman A.

Proc Natl Acad Sci U S A. 2018 May 22;115(21):5534-5539. doi: 10.1073/pnas.1721559115. Epub 2018 May 7.

PMID:  29735668


Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.

Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, Landi I, Hsu V, Duggan M, Wesolowski R, Old M, Howard JH, Yu L, Stasik N, Olencki T, Muthusamy N, Tridandapani S, Byrd JC, Caligiuri M, Carson WE.

Clin Cancer Res. 2018 Apr 15;24(8):1891-1904. doi: 10.1158/1078-0432.CCR-17-0691. Epub 2018 Jan 23.

PMID: 29363526


Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity.

Suarez-Kelly LP, Akagi K, Reeser JW, Samorodnitsky E, Reeder M, Smith A, Roychowdhury S, Symer DE, Carson WE.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002352. doi: 10.1101/mcs.a002352. Print 2018 Apr.

PMID:  29449315


Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.

Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE.

Sci Rep. 2018 Mar 6;8(1):4203. doi: 10.1038/s41598-018-21306-z.

PMID:  29511220


Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.

Xu J, Regan-Fendt K, Deng S, Carson WE, Payne PRO, Li F.

Pac Symp Biocomput. 2018;23:92-103.

PMID:  29218872


Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.

Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE.

Sci Rep. 2017 Nov 13;7(1):15424. doi: 10.1038/s41598-017-14970-0. Erratum in: Sci Rep. 2018 Mar 6;8(1):4203.

PMID:  29133913


Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.

Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE 3rd.

Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447. doi: 10.1007/s00262-017-2038-3. Epub 2017 Jul 7.

PMID:  28688082


Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.

Duggan MC, Stiff AR, Bainazar M, Regan K, Olaverria Salavaggione GN, Maharry S, Blachly JS, Krischak M, Walker CJ, Latchana N, Tridandapani S, de la Chapelle A, Eisfeld AK, Carson WE 3rd.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9629-9634. doi: 10.1073/pnas.1704371114. Epub 2017 Aug 21.

PMID:  28827320


MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions.

Campbell AR, Duggan MC, Suarez-Kelly LP, Bhave N, Opheim KS, McMichael EL, Trikha P, Parihar R, Luedke E, Lewis A, Yung B, Lee R, Raulet D, Tridandapani S, Groh V, Yu L, Yildiz V, Byrd JC, Caligiuri MA, Carson WE 3rd.

Cancer Immunol Res. 2017 Sep;5(9):778-789. doi: 10.1158/2326-6066.CIR-16-0005. Epub 2017 Jul 19.

PMID:  28724544


Novel rodent model of breast cancer survival with persistent anxiety-like behavior and inflammation.

Pyter LM, Suarez-Kelly LP, Carson WE 3rd, Kaur J, Bellisario J, Bever SR.

Behav Brain Res. 2017 Jul 14;330:108-117. doi: 10.1016/j.bbr.2017.05.011. Epub 2017 May 4.

PMID:  28479263


Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T.

J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2.

PMID:  28463630


Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O’Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

PMID:  27906454


Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.

Suarez-Kelly LP, Campbell AR, Rampersaud IV, Bumb A, Wang MS, Butchar JP, Tridandapani S, Yu L, Rampersaud AA, Carson WE 3rd.

Nanomedicine. 2017 Apr;13(3):909-920. doi: 10.1016/j.nano.2016.12.005. Epub 2016 Dec 18.

PMID:  27993723


Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.

PMID:  28135150


Plasma MicroRNA Levels Following Resection of Metastatic Melanoma.

Latchana N, Abrams ZB, Howard JH, Regan K, Jacob N, Fadda P, Terando A, Markowitz J, Agnese D, Payne P, Carson WE 3rd.

Bioinform Biol Insights. 2017 Feb 23;11:1177932217694837. doi: 10.1177/1177932217694837. eCollection 2017.

PMID: 28469417